These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

505 related items for PubMed ID: 23451917

  • 1. Sustained remissions of immune thrombocytopenia associated with the use of thrombopoietin receptor agonists.
    Ghadaki B, Nazi I, Kelton JG, Arnold DM.
    Transfusion; 2013 Nov; 53(11):2807-12. PubMed ID: 23451917
    [Abstract] [Full Text] [Related]

  • 2. Thrombopoietin Receptor Agonists in the Treatment of Chronic Resistant Primary Immune Thrombocytopenia: Efficacy and Safety Data in Real Clinical Practice.
    Ptushkin VV, Vinogradova OY, Pankrashkina MM, Chernikov MV, Arshanskaya EG, Tkachenko NE.
    Ter Arkh; 2018 Aug 17; 90(7):70-76. PubMed ID: 30701925
    [Abstract] [Full Text] [Related]

  • 3. Thrombopoietin Receptor Agonists: Eltrombopag and Romiplostim for the Treatment of Chronic Immune Thrombocytopenia Purpura.
    Atkinson K.
    Clin J Oncol Nurs; 2019 Apr 01; 23(2):212-216. PubMed ID: 30880797
    [Abstract] [Full Text] [Related]

  • 4. Thrombopoietin Receptor Agonist Use in Children: Data From the Pediatric ITP Consortium of North America ICON2 Study.
    Neunert C, Despotovic J, Haley K, Lambert MP, Nottage K, Shimano K, Bennett C, Klaassen R, Stine K, Thompson A, Pastore Y, Brown T, Forbes PW, Grace RF, Pediatric ITP Consortium of North America (ICON).
    Pediatr Blood Cancer; 2016 Aug 01; 63(8):1407-13. PubMed ID: 27135461
    [Abstract] [Full Text] [Related]

  • 5. The use of thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): a "real life" retrospective multicenter experience of the Rete Ematologica Pugliese (REP).
    Mazza P, Minoia C, Melpignano A, Polimeno G, Cascavilla N, Di Renzo N, Specchia G.
    Ann Hematol; 2016 Jan 01; 95(2):239-44. PubMed ID: 26596973
    [Abstract] [Full Text] [Related]

  • 6. Thrombopoietin receptor agonists for preparing adult patients with immune thrombocytopenia to splenectomy: results of a retrospective, observational GIMEMA study.
    Zaja F, Barcellini W, Cantoni S, Carpenedo M, Caparrotti G, Carrai V, Di Renzo N, Santoro C, Di Nicola M, Veneri D, Simonetti F, Liberati AM, Ferla V, Paoloni F, Crea E, Volpetti S, Tuniz E, Fanin R.
    Am J Hematol; 2016 May 01; 91(5):E293-5. PubMed ID: 26910388
    [Abstract] [Full Text] [Related]

  • 7. Thrombopoietin Receptor Agonists in Children with Immune Thrombocytopenia: A New Therapeutic Era.
    Lassandro G, Palladino V, Vecchio GCD, Palmieri VV, Corallo PC, Faienza MF, Giordano P.
    Endocr Metab Immune Disord Drug Targets; 2021 May 01; 21(3):397-406. PubMed ID: 32473624
    [Abstract] [Full Text] [Related]

  • 8. Thrombopoietin receptor agonists in refractory immune thrombocytopenia: differential responses to eltrombopag and romiplostim: a case report and possible explanations.
    Aoki T, Harada Y, Matsubara E, Suzuki T, Oyama T, Kasai M, Uchida T, Ogura M.
    J Clin Pharm Ther; 2012 Dec 01; 37(6):729-32. PubMed ID: 22583038
    [Abstract] [Full Text] [Related]

  • 9. Real-world use of thrombopoietin receptor agonists for the management of immune thrombocytopenia in adult patients in the United Kingdom: Results from the TRAIT study.
    Cooper N, Scully M, Percy C, Nicolson PLR, Lowe G, Bagot CN, Thachil J, Grech H, Nokes T, Hill QA, Bradbury C, Talks K, Dutt T, Evans G, Pavord S, Wexler S, Charania A, Collington SJ, Ervin A, Ramscar N, Provan D.
    Br J Haematol; 2024 Jun 01; 204(6):2442-2452. PubMed ID: 38429869
    [Abstract] [Full Text] [Related]

  • 10. Treatment patterns and clinical outcomes in patients with chronic immune thrombocytopenia (ITP) switched to eltrombopag or romiplostim.
    Kuter DJ, Macahilig C, Grotzinger KM, Poston SA, Wang PF, Dawson KL, Ward M.
    Int J Hematol; 2015 Mar 01; 101(3):255-63. PubMed ID: 25586660
    [Abstract] [Full Text] [Related]

  • 11. Thrombopoietin receptor agonist switch in adult primary immune thrombocytopenia patients: A retrospective collaborative survey involving 4 Spanish centres.
    Lakhwani S, Perera M, Fernández-Fuertes F, Ríos de Paz MA, Torres M, Raya JM, Hernández MT.
    Eur J Haematol; 2017 Oct 01; 99(4):372-377. PubMed ID: 28759125
    [Abstract] [Full Text] [Related]

  • 12. The temporary use of thrombopoietin-receptor agonists may induce a prolonged remission in adult chronic immune thrombocytopenia. Results of a French observational study.
    Mahévas M, Fain O, Ebbo M, Roudot-Thoraval F, Limal N, Khellaf M, Schleinitz N, Bierling P, Languille L, Godeau B, Michel M.
    Br J Haematol; 2014 Jun 01; 165(6):865-9. PubMed ID: 24725224
    [Abstract] [Full Text] [Related]

  • 13. [Successful switching from eltrombopag to romiplostim in a pediatric patient with refractory chronic ITP].
    Mori M, Kato M, Koh K, Hanada R.
    Rinsho Ketsueki; 2015 May 01; 56(5):511-3. PubMed ID: 26062675
    [Abstract] [Full Text] [Related]

  • 14. Thrombopoietin-receptor agonists for children with immune thrombocytopenia: a systematic review.
    Zhang J, Liang Y, Ai Y, Xie J, Li Y, Zheng W.
    Expert Opin Pharmacother; 2017 Oct 01; 18(15):1543-1551. PubMed ID: 28845713
    [Abstract] [Full Text] [Related]

  • 15. Relative potency of the thrombopoietin receptor agonists eltrombopag, avatrombopag and romiplostim in a patient with chronic immune thrombocytopenia.
    Al-Samkari H, Kuter DJ.
    Br J Haematol; 2018 Oct 01; 183(2):168. PubMed ID: 29978577
    [No Abstract] [Full Text] [Related]

  • 16. Effect of a thrombopoietin receptor agonist on use of intravenous immune globulin in patients with immune thrombocytopenia.
    Zeller MP, Heddle NM, Kelton JG, Hamilton K, Wang G, Sholapur N, Carruthers J, Hsia C, Blais N, Toltl L, Hamm C, Pearson MA, Arnold DM.
    Transfusion; 2016 Jan 01; 56(1):73-9. PubMed ID: 26400824
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim: A multicentre US study.
    Al-Samkari H, Jiang D, Gernsheimer T, Liebman H, Lee S, Wojdyla M, Vredenburg M, Cuker A.
    Br J Haematol; 2022 May 01; 197(3):359-366. PubMed ID: 35179784
    [Abstract] [Full Text] [Related]

  • 19. Long-term use of the thrombopoietin-mimetic romiplostim in children with severe chronic immune thrombocytopenia (ITP).
    Bussel JB, Hsieh L, Buchanan GR, Stine K, Kalpatthi R, Gnarra DJ, Ho RH, Nie K, Eisen M.
    Pediatr Blood Cancer; 2015 Feb 01; 62(2):208-213. PubMed ID: 25345874
    [Abstract] [Full Text] [Related]

  • 20. Deciphering predictive factors for choice of thrombopoietin receptor agonist, treatment free responses, and thrombotic events in immune thrombocytopenia.
    Lozano ML, Mingot-Castellano ME, Perera MM, Jarque I, Campos-Alvarez RM, González-López TJ, Carreño-Tarragona G, Bermejo N, Lopez-Fernandez MF, de Andrés A, Valcarcel D, Casado-Montero LF, Alvarez-Roman MT, Orts MI, Novelli S, Revilla N, González-Porras JR, Bolaños E, Rodríguez-López MA, Orna-Montero E, Vicente V.
    Sci Rep; 2019 Nov 13; 9(1):16680. PubMed ID: 31723222
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.